Karl Weiss

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

Oliver A. Cornely, Derrick W. Crook, Roberto Esposito et al. · The Lancet Infectious Diseases · 2012 · 739 citations

Fidaxomicin Versus Vancomycin, Antimicrobial Susceptibility, Health Sciences +8

Effect of a Fermented Milk Combining<i>Lactobacillus Acidophilus</i>CL1285 and<i>Lactobacillus Casei</i>in the Prevention of Antibiotic-Associated Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Trial

Mélanie Beausoleil, Nadia Fortier, Stéphanie Guénette et al. · Canadian Journal of Gastroenterology · 2007 · 163 citations · Full text

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

Richard Vickers, Glenn Tillotson, Richard Nathan et al. · The Lancet Infectious Diseases · 2017 · 115 citations · Full text

Multicenter, Randomized Clinical Trial To Compare the Safety and Efficacy of LFF571 and Vancomycin for Clostridium difficile Infections

Kathleen M. Mullane, Christine Lee, Adam Bressler et al. · Antimicrobial Agents and Chemotherapy · 2014 · 100 citations · Full text

Randomized Clinical Trial, Serious Diarrheal Disease, Pharmacotherapy +17

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma

Ho Yeong Lim, Philippe Merle, Karl Weiss et al. · Clinical Cancer Research · 2018 · 78 citations · Full text